Jeannette Potts Sells 5,237 Shares of uniQure N.V.
uniQure's Chief Legal Officer, Jeannette Potts, sold shares worth $144,907.79.
Key Points
- Jeannette Potts, Chief Legal Officer at uniQure N.V., sold 5,237 shares on June 15, 2026, at an average price of $27.67, totaling $144,907.79.
- uniQure N.V. trades on NasdaqGS under the ticker QURE, with a market cap of $1.70 billion and a 52-week range between $8.73 and $71.50.
- Analysts from firms like HC Wainwright & Co. and Chardan Capital maintain a 'buy' rating for uniQure, with price targets ranging from $10 to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jeannette Potts, the Chief Legal Officer at uniQure N.V. (NasdaqGS: QURE), sold 5,237 shares of the company on June 15, 2026. The shares were sold at an average price of $27.67 each, amounting to a total transaction value of $144,907.79. This sale was not part of a pre-planned trading program.
Insider Buying and Selling at uniQure N.V.
On the same day, another insider, Balachandran Madhavan, bought 10,000 shares at $8.49, while also selling 10,000 shares at $27.85 in a planned transaction. Rachelle Suzanne Jacques and Robert Gut also sold shares on June 11, 2026, at a price of $27.06 each.
Other Institutional Activity in uniQure N.V.
Aberdeen Group PLC increased its holdings in uniQure by 1,627,746 shares, ending with 5,306,386 shares valued at about $86.76 million. Meanwhile, Two Sigma Investments, LP grew its stake by 1,224,587 shares, resulting in a total of 2,675,871 shares worth $43.75 million. In contrast, RTW Investments, LP reduced its holdings by 1,125,106 shares, leaving it with 2,586,356 shares valued at $42.29 million.
uniQure N.V. Stock Down 44.6%
Shares of uniQure N.V. traded at approximately $26.99. The company has a market capitalization of $1.70 billion and a forward P/E ratio of -9.55, indicating it is not currently profitable. Its beta stands at 1.001, suggesting average market volatility. The stock's 52-week range is between $8.73 and $71.50, with a 50-day moving average of $22.90 and a 200-day moving average of $27.22. The company's current ratio is 10.40, and its quick ratio is 9.97, while its debt-to-equity ratio is significantly high at 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 6, 2026, HC Wainwright & Co. maintained its 'buy' rating for uniQure with a price target of $50. Chardan Capital also maintained a 'buy' rating with a target of $37 on April 30, 2026. Goldman Sachs held a 'hold' rating with a $10 target on April 20, 2026. The consensus among 11 analysts is a 'buy' rating, with a mean price target of $39.11.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing treatments for rare and serious diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B by enabling them to produce factor IX, reducing bleeding risks. The company is also advancing AMT-130, a gene therapy for Huntington's disease, and other therapies targeting epilepsy, ALS, and Fabry disease. uniQure collaborates with Apic Bio and CLS Bhering for gene therapy development and commercialization.
Bottom Line
Jeannette Potts' recent share sale is part of the ongoing insider activity at uniQure N.V. Investors closely watch insider transactions for potential insights into company performance. The stock is currently trading within a broad 52-week range, and analysts maintain a generally positive outlook with several 'buy' ratings. As always, these insights are based on past filings and may not reflect current positions.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.